Imagine a world where the most abundant immune cells in the human body, crucial for fighting infections, remain a mysterious black box to scientists and medical professionals. For too long, neutrophils—those rapid-response warriors of the immune system—have been just that, with their complex
Imagine a world where the trial-and-error nature of drug discovery is replaced by a precise, predictive system capable of designing therapies for some of humanity’s most stubborn diseases. This vision is no longer a distant dream but a tangible goal for insitro, a South San Francisco-based AI
Imagine a world where life-saving drugs reach patients faster, with fewer animals harmed and costs slashed by millions. This isn’t a distant dream but a tangible goal as the U.S. Food and Drug Administration (FDA) pivots toward human-relevant drug safety models. With new draft guidance released
Imagine a world where the intricate dance of molecules within the brain can be captured in stunning detail, offering a roadmap to tackle one of neurology’s most persistent challenges—epilepsy. This vision is becoming reality thanks to cryo-electron microscopy (Cryo-EM), a cutting-edge technology
Imagine a world where a diagnosis of gastric cancer no longer carries the weight of a dire prognosis, where innovative treatments offer a real chance at long-term survival even for those in the early stages of this aggressive disease. This vision is inching closer to reality with the recent
A therapy that should unleash the immune system instead fuels a tumor’s growth, and the only way to see why is to listen to each cell speak for itself; that is the everyday paradox that single-cell RNA sequencing (scRNA-seq) now makes decipherable in real time. In oncology, this shift from average
